SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Nov 24, 2015

Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: Nov. 24, 2015 · CIK: 0001213037 · Accession: 0001104659-15-081168

AI Filing Summary & Sentiment

File numbers found in text: 333-208010

Date
November 24, 2015
Author
Not clearly detected
Form
CORRESP
Company
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)

Letter

Trovagene, Inc.

11055 Flintkote Avenue

San Diego, CA 92921

November 24, 2015

VIA EDGAR

United States Securities

and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Scot Foley

Re: Trovagene Inc.

Registration Statement on Form S-3

File No. 333-208010

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 9 a.m., Eastern Standard Time, on Monday, November 30, 2015, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

TROVAGENE, INC.

By:

/s/ Antonius Schuh

Name: Antonius Schuh

Title: Chief Executive Officer

Show Raw Text
CORRESP
1
filename1.htm

Trovagene, Inc.

11055 Flintkote Avenue

San Diego, CA 92921

November 24, 2015

VIA EDGAR

United States Securities

and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Scot Foley

Re:                             Trovagene Inc.

Registration Statement on Form S-3

File No. 333-208010

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 9 a.m., Eastern Standard Time, on Monday, November 30, 2015, or as soon thereafter as possible.  The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert  the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

TROVAGENE, INC.

By:

/s/   Antonius Schuh

Name: Antonius Schuh

Title:   Chief Executive Officer